Teva Pharmaceutical Industries Limited · NYSE
Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about TEVA?
GlobeNewswire Inc.
Teva to Host R&D Day on Wednesday, November 11 in New York CityTeva Pharmaceutical Industries announced it will host an R&D Day on November 11, 2026, in New York to discuss its R&D pipeline and transformation strategy into an innovative biopharma company. The company also announced FDA approval of WELTRUZA™ (olanzapine), the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.
Zacks Investment Research
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in SchizophreniaTeva Pharmaceutical Industries announced FDA approval of Weltruza (olanzapine) extended-release injectable suspension, the first once-monthly subcutaneous formulation for treating schizophrenia in adults. The drug will launch in the U.S. in coming weeks with three dosage strengths and requires no loading doses or post-injection monitoring. This approval expands Teva's schizophrenia portfolio alongside its existing Uzedy product, which generated $140 million in sales in the first half of 2026.
Headlines link to the publisher. Not investment advice.
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Sign in to post on $TEVA
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
